Better Times Ahead For Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP)?


Citadel Advisors LLC has recently announced that it has increased stake in Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) by 427.34%. After grabbing 0.44 million shares, the institutional investor is now in possession of 0.36 million shares of the Healthcare Company. The new investment brought the stake of investor firm to 0.35% having worth around $0.57 million. Moreover, Bridgeway Capital Management, Inc.. increased its share by 0.26 million to have a control over 0.26 million shares. And Geode Capital Management LLC raised its holdings to 22147.0 shares by acquiring 0.11 million shares or 0.09% of the stake.

Tonix Pharmaceuticals Holding Corp. (TNXP) concluded trading on 08/27/20 at a closing price of $0.97, with 12.31 million shares of worth about $11.95 million changed hands on the day. Weekly performance of the stock remained positive as price took a surge of 4.87% during that period and on Thursday the price saw a gain of about 1.73%. Currently the company’s common shares owned by public are about 130.27M shares, out of which, 130.14M shares are available for trading.

A deeper look into what the analysts at Wall Street are thinking about the price target of this stock provides us with the following: 1 analyst is covering the TNXP stock and their offered price forecasts bring an average price target of $3.00. Over the next 12 months, analysts forecasted that the stock’s price could jump as high as $3.00 and could fall to a lowest price of $3.00. Analysts also issued an outlook of 2.00 for the Tonix Pharmaceuticals Holding Corp. stock for next 12 months. However, touching the estimated high of $3.00 would mean a gain of 67.67% for the stock.

According to filings with the U.S. Securities and Exchange Commission (SEC), insiders took part in trade of the company’s stock for 5 times over the past 12 months. They bought 45,241 shares in 5 of the transactions. In 0 selling transactions, insiders dumped 0 shares.

Vanguard Extended Market Index Fu, Bridgeway Ultra Small Company Mar, and Fidelity Extended Market Index Fu are the top 3 mutual funds which are holding stakes in Tonix Pharmaceuticals Holding Corp. Vanguard Extended Market Index Fu is currently holding 0.44 million shares of worth totaling $0.57 million. The company recently came buying 61080.0 shares which brought its stake up to 0.35% of the company’s outstanding shares. Fidelity Extended Market Index Fu, after buying 83212.0 shares, have now control over 0.07% of the stake in the company. It holds 0.0 shares of worth $0.11 million.

Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) started trading at $0.9155, below -$0.03 from concluding price of the previous day. However, the stock finished the trading on the day at a closing price of $0.97, or with a gain of 1.73%. Stock saw a price change of 4.87% in past 5 days and over the past one month there was a price change of -14.82%. Year-to-date (YTD), TNXP shares are showing a performance of -17.00% which decreased to -76.55% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.39 but also hit the highest price of $5.38 during that period. While comparing its average daily trading volume of 24.97 million shares, we see that about 12.31 million changed hands on the day. The stock is currently trading -8.91% below its 20-day simple moving average (SMA20), while that difference is up 5.48% for SMA50 and it goes to 0.14% higher than SMA200.

Citadel Advisors LLC acquired 0.44 million shares of Tonix Pharmaceuticals Holding Corp. having value of about $0.57 million. Data submitted at the U.S SEC by Citadel Advisors LLC revealed that the firm now holds 0.36 million shares in the company valued at close to $348075.77, or have control over 427.34% stake in the company. Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) currently have 130.27M outstanding shares and institutions hold larger chunk of about 3.50% of that. Holding of mutual funds in the company is about 0.58% while other institutional holders and individual stake holders have control over 0.60% and 0.11% of the stake respectively.

The stock has a current market capitalization of $133.23M and its 3Y-monthly beta is at 1.76. It has posted earnings per share of -$59.29 in the same period. It has Quick Ratio of 12.30 while making debt-to-equity ratio of 0.00. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for TNXP, volatility over the week remained 11.97% while standing at 12.12% over the month.

Analysts are in expectations that Tonix Pharmaceuticals Holding Corp. (TNXP) stock would likely to be making an EPS of -$0.16 in the current quarter, while forecast for next quarter ESPS is -$0.16 and it is -$0.48 for next year. For the current quarter EPS, analysts have given the company a lowest target -$0.21 which is -$0.11 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -$5.69 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 92.80% while it is estimated to increase by 50.00% in next year.

Analysts at 1 brokerage firms have issued recommendations for the Tonix Pharmaceuticals Holding Corp. (TNXP)’s stock and average of those rates the stock at a “Moderate Buy” and assign it a score of 2.00. Out of those 1 Wall Street analysts, 1 recommended a “Buy” rating, while 0 were in favor recommending the stock as a “Hold” and 0 analyst recommended the stock as “Sell”.

Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by ROTH Capital on April 18, 2019 offering a Buy rating for the stock and assigned a target price of $4 to it. Coverage by ROTH Capital stated Tonix Pharmaceuticals Holding Corp. (TNXP) stock as a Buy in their note to investors on August 18, 2017, suggesting a price target of $6 for the stock. On September 07, 2016, ROTH Capital Downgrade their recommendations, while on February 17, 2016, Oppenheimer Reiterated their ratings for the stock with a price target of $10. Stock get a Buy rating from Cantor Fitzgerald on November 04, 2015.


Please enter your comment!
Please enter your name here